Minimal residual disease monitoring in chronic myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation using interphase fluorescence in situ hybridization and real-time quantitative reverse transcription PCR.
- Author:
Hong-Qian ZHU
1
;
Xiao-Li LIU
;
Lan-Lin SONG
;
Qi-Fa LIU
;
Fan-Yi MENG
;
Shu-Yun ZHOU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Child; Female; Fusion Proteins, bcr-abl; genetics; metabolism; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; metabolism; pathology; therapy; Male; Neoplasm, Residual; RNA, Messenger; metabolism; Reverse Transcriptase Polymerase Chain Reaction; Young Adult
- From:Chinese Journal of Cancer 2010;29(2):194-197
- CountryChina
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVEInterphase fluorescence in situ hybridization (FISH) and real-time quantitative reverse transcription PCR (RQ-PCR) are the common methods for monitoring minimal residual disease (MRD) in chronic myeloid leukemia (CML) patients. This study was to assess the value of monitoring BCR-ABL fusion gene level in CML patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) using FISH and RQ-PCR.
METHODSBCR-ABL fusion gene levels were detected in the bone marrow of 31 patients with CML before and 3-48 months after allo-HSCT using FISH and RQ-PCR.
RESULTSBCR-ABL positive cells detected by FISH were decreased 3-30 months after allo-HSCT and BCR-ABL/ABL mRNA was reduced by 2 logarithmic units in RQ-PCR (P < 0.05). While no BCR-ABL positive cell was detected by FISH 30 months after allo-HSCT, BCR-ABL/ABL mRNA was detected by RQ-PCR and declined by more than 3 logarithmic units, (P < 0.05).
CONCLUSIONSDynamic monitoring of BCR-ABL gene on molecular level in CML patients after allo-HSCT is useful in the early prediction of susceptibility to recurrence in the patients and in designing intervention, and is thus helpful in improving the overall survival rate after transplantation.